Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
[Editor's Note: This is part two of a two-part interview. Part one appeared May 4, 2008 in PharmAsia News.]
You may also be interested in...
Quick Take: AstraZeneca Pursues Traditional Chinese Medicine As New Source For R&D
AstraZeneca signs research collaboration with Shanghai’s Fudan University to investigate mechanism of action for a TCM compound to treat cardiovascular disease.
Novartis Lines Up $1 Billion For China R&D
Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space
Novartis Lines Up $1 Billion For China R&D
Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space